Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Subramani, Ramadevi ^a   Lopez Valdez, Rebecca ^a   Arumugam, Arunkumar ^a   Nandy, Sushmita ^a   Boopalan, Thiyagarajan ^a   Lakshmanaswamy, Rajkumar ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; INSULIN RECEPTOR BETA; JANUS KINASE; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE SILENCING; HPAC CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METASTASIS INHIBITION; PANC 1 CELL LINE; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WOUND HEALING; CELL MOTION; CELL PROLIFERATION; DEFICIENCY; GENETICS; METASTASIS; MOLECULARLY TARGETED THERAPY; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84901049446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097016     Document Type: Article

References (48)

1. Fang Y, Yao Q, Chen Z, Xiang J, William FE, et al. (2013) Genetic and molecular alterations in pancreatic cancer: Implications for personalized medicine. Medical science monitor : international medical journal of experimental and clinical research 19: 916-926.
2. Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D (2013) Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Frontiers in pharmacology 4: 56.
3. Ashour AA, Abdel-Aziz AA, Mansour AM, Alpay SN, Huo L, et al. (2013) Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells. Apoptosis : An International Journal on Programmed Cell Death.
4. Cao H, Le D, Yang LX (2013) Current status in chemotherapy for advanced pancreatic adenocarcinoma. Anticancer Research 33: 1785-1791.
5. Costello LC, Franklin RB (2013) A Review of the Current Status and Concept of the Emerging Implications of Zinc and Zinc Transporters in the Development of Pancreatic Cancer. Pancreatic disorders & therapy Suppl 4: 002.
6. Cheng H, Shi S, Cai X, Long J, Xu J, et al. (2012) microRNA signature for human pancreatic cancer invasion and metastasis. Exp Ther Med 4: 181-187.
7. Longati P, Jia X, Eimer J, Wagman A, Witt MR, et al. (2013) 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC cancer 13: 95-2407-2413-2495.
8. Nair PN, De Armond DT, Adamo ML, Strodel WE, Freeman JW (2001) Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 20: 8203-8214. (Pubitemid 34038209)
9. Chaves J, Saif MW (2011) IGF system in cancer: from bench to clinic. Anti-Cancer Drugs 22: 206-212.
10. Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, et al. (2012) Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 118: 3993-4003.
11. Tang J, Li J, Zeng G, Tang Y, Tian W, et al. (2013) Antisense oligonucleotide suppression of human IGF-1R inhibits the growth and survival of in vitro cultured epithelial ovarian cancer cells. Journal of ovarian research 6: 71-2215-2216-2271.
12. Kamrava M, Gius D, Casagrande G, Kohn E (2011) Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective. Ageing research reviews 10: 62-70.
13. Delafontaine P, Song YH, Li Y (2004) Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 435-444. (Pubitemid 38326135)
14. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY) 321: 1801-1806.
15. Cardillo TM, Trisal P, Arrojo R, Goldenberg DM, Chang CH (2013) Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC cancer 13: 170-2407-2413-2170.
16. Leiphrakpam PD, Agarwal E, Mathiesen M, Haferbier KL, Brattain MG, et al. (2013) In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer. Oncology reports.
17. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, et al. (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Journal of the National Cancer Institute 94: 1099-1106. (Pubitemid 34830730)
18. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, et al. (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. Journal of the National Cancer Institute 91: 620-625. (Pubitemid 29194048)
19. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, et al. (2002) Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Investigative ophthalmology & visual science 43: 1-8. (Pubitemid 34032432)
20. Qin B, Cheng K (2010) Silencing of the IKKepsilon gene by siRNA inhibits invasiveness and growth of breast cancer cells. Breast cancer research : BCR 12: R74.
21. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science (New York, NY) 331: 1559-1564.
22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715. (Pubitemid 351636299)
23. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, et al. (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer research 68: 3645-3654.
24. Roy SK, Srivastava RK, Shankar S (2010) Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. Journal of molecular signaling 5: 10-2187-2185-2110.
25. Garcia-Carracedo D, Turk AT, Fine SA, Akhavan N, Tweel BC, et al. (2013) Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Clinical cancer research : an official journal of the American Association for Cancer Research.
26. Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, et al. (2013) Emerging therapeutic paradigms to target the dysregulated JAK/STAT pathways in hematological malignancies. Leukemia & lymphoma.
27. Zumsteg A, Caviezel C, Pisarsky L, Strittmatter K, Garcia-Echeverria C, et al. (2012) Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma. Molecular cancer research : MCR 10: 800-809.
28. Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, et al. (2010) Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World J Gastroenterol 16: 1854-1858.
29. Yamada S, Fuchs BC, Fujii T, Shimoyama Y, Sugimoto H, et al. (2013) Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery 154: 946-954.
30. Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Torres-Garcia VZ, Corominas-Faja B, et al. (2013) IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep 3: 2560.
31. Bahr C, Groner B (2005) The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 23: 1-14. (Pubitemid 41656866)
32. Galet C, Gray A, Said JW, Castor B, Wan J, et al. (2013) Effects of Calorie Restriction and IGF-1 Receptor Blockade on the Progression of 22Rv1 Prostate Cancer Xenografts. International journal of molecular sciences 14: 13782-13795.
33. Chen HX, Sharon E (2013) IGF-1R as an anti-cancer target-trials and tribulations. Chinese journal of cancer 32: 242-252.
34. Morrione A, Valentinis B, Xu SQ, Yumet G, Louvi A, et al. (1997) Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proceedings of the National Academy of Sciences of the United States of America 94: 3777-3782.
35. Scagliotti GV, Novello S (2012) The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer treatment reviews 38: 292-302.
36. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, et al. (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes & development 11: 701-713. (Pubitemid 27157159)
37. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, et al. (2001) Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083. (Pubitemid 32955050)
38. Kaufmann SH, Hengartner MO (2001) Programmed cell death: alive and well in the new millennium. Trends in cell biology 11: 526-534. (Pubitemid 33079147)
39. Kandasamy K, Srivastava RK (2002) Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer research 62: 4929-4937. (Pubitemid 34984416)
40. Downward J (2004) PI 3-kinase, Akt and cell survival. Seminars in cell & developmental biology 15: 177-182.
41. Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W, et al. (2002) Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 24: 42-46. (Pubitemid 34019658)
42. Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, et al. (2013) Target Therapies In Pancreatic Carcinoma. Current medicinal chemistry.
43. Pothiwala P, Jain SK, Yaturu S (2009) Metabolic syndrome and cancer. Metabolic syndrome and related disorders 7: 279-288.
44. Braun S, Bitton-Worms K, LeRoith D (2011) The link between the metabolic syndrome and cancer. International journal of biological sciences 7: 1003-1015.
45. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, et al. (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer prevention research (Philadelphia, Pa) 4: 329-346.
46. Khan S, Shukla S, Sinha S, Meeran SM (2013) Role of adipokines and cytokines in obesity-associated breast cancer: Therapeutic targets. Cytokine & growth factor reviews.
47. St-Germain ME, Gagnon V, Mathieu I, Parent S, Asselin E (2004) Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. International journal of oncology 24: 1311-1324.
48. Philip B, Roland CL, Daniluk J, Liu Y, Chatterjee D, et al. (2013) A High-Fat Diet Activates Oncogenic Kras and COX2 to Induce Development of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology 145: 1449-1458.